Clinical Trial Update: Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013] [Phase 2]

View source ↗

Summary

A Phase 2 dose-ranging switch study (MK-8591-013) evaluating once-weekly islatravir and ulonivirine in virologically suppressed adults with HIV-1; results have …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Islatravir (Islatravir)
• Ulonivirine (MK-8507)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: HIV-1 Infection | Phase 2 | Status: COMPLETED | Results posted: 2026-01-26